探索CAR-T细胞耐药性的前沿:从潜在机制到创新的治疗解决方案
Fei Lan1, Jin Song1, Xinfeng Chen2
1Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
Molecular immunology
|March 6, 2026
概括
化学抗原受体 (CAR) -T细胞疗法对血液癌症有希望,但面临阻力. 本综述探讨了耐药性机制和策略,如双重向和TME重编程,以提高CAR-T细胞治疗的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法在治疗血液性恶性瘤方面取得了显著的成功,例如B细胞急性淋巴细胞白血病,B细胞淋巴瘤和多发性髓瘤.
- 然而,挑战仍然存在,包括血液癌症的耐药性和对固体瘤的免疫反应不足,限制了其更广泛的应用.
研究的目的:
- 系统地审查各种癌症中对CAR-T细胞治疗的抵抗机制.
- 讨论和评估克服这些抵抗机制和增强治疗结果的潜在策略.
主要方法:
- 对CAR-T细胞治疗耐药性的现有文献进行系统审查.
- 分析导致治疗失败的关键机制,包括瘤抗原损失,亡信号失调,CAR-T细胞功能障碍和免疫抑制瘤微环境 (TME).
主要成果:
- 对CAR-T细胞疗法的耐药性由多种因素介导,包括瘤抗原逃逸,T细胞功能受损和敌对的TME.
- 这些机制显著损害了CAR-T细胞治疗在血液和固体瘤中的疗效.
结论:
- 克服耐药性需要多方面的方法,包括双重目标策略,先进的CAR工程,TME调制和组合免疫疗法.
- 对这些对策的进一步研究对于优化CAR-T细胞治疗和扩大其临床实用性至关重要.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
Development of Antibiotic Resistance
1.7K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.7K
Cell-mediated Immune Responses
85.4K
Overview
85.4K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)